2895 studies found for:
Open Studies | "Carcinoma"
| Rank | Status | Study | ||||
|---|---|---|---|---|---|---|
| 1 | Recruiting |
A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
|
||||
| 2 | Recruiting |
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
|
||||
| 3 | Recruiting |
A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology
|
||||
| 4 | Recruiting |
Fludeoxyglucose F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer
|
||||
| 5 | Recruiting |
Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer
|
||||
| 6 | Not yet recruiting |
Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence
|
||||
| 7 | Recruiting |
Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed By Surgery
|
||||
| 8 | Recruiting |
Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma
|
||||
| 9 | Recruiting |
Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy
|
||||
| 10 | Recruiting |
First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
|
||||
| 11 | Recruiting |
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
|
||||
| 12 | Recruiting |
Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell Carcinoma
|
||||
| 13 | Recruiting |
Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)
|
||||
| 14 | Recruiting |
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
|
||||
| 15 | Unknown † |
Microarray Analysis of Gene Expression and Identification of Progenitor Cells in Lung Carcinoma
|
||||
| 16 | Unknown † |
Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma
|
||||
| 17 | Recruiting |
Phase II Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)
|
||||
| 18 | Recruiting |
Oral Rigosertib for Squamous Cell Carinoma
|
||||
| 19 | Not yet recruiting |
Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma
|
||||
| 20 | Recruiting |
S-1/LV One Week on and One Week Off Regimen in Advanced Hepatocellular Carcinoma (HCC)
|
† Indicates status has not been verified in more than two years
